Navigation Links
Pharmathene Reports Third Quarter 2008 Financial and Operational Results

ANNAPOLIS, Md., Nov. 13 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the third quarter and nine months ended September 30, 2008.

For the third quarter of 2008, PharmAthene recognized revenues of $10.7 million compared to $3.4 million in the same period of 2007. For the nine months ended September 30, 2008 and 2007, the Company reported revenues of $27.4 million and $8.7 million, respectively. These revenues consisted primarily of contract funding from the U.S. government for the development of the Company's medical countermeasures, Protexia(R), SparVax(TM) and RypVax(TM). As a result of the Avecia vaccines acquisition in the second quarter of 2008, and particularly the acquired U.S. government contracts supporting the development of the rPA anthrax vaccines and RypVax(TM) plague vaccine product candidates, revenues for the three and nine month periods ended September 30, 2008 were further boosted by $5.5 million and $8.9 million, respectively.

Research and development expenses were $9.4 million and $3.6 million for the quarter ended September 30, 2008 and 2007, respectively. For the nine months ended September 30, 2008 and 2007, research and development expenses were $26.5 million and $10.7 million, respectively. Expenses for the third quarter and nine months of 2008 resulted from research and development activities related to programs for Valortim(R) and Protexia(R) as well as expenses related to the Company's SparVax(TM) and RypVax(TM) programs, which were acquired in the second quarter of 2008. The increase in research and development expenses is primarily due to process development expenses, manufacturing activities and clinical development expenses related to the Company's programs.

General and administrative expenses for the Company were $4.8 million and $3.2 million for the quarter ended September 30, 2008 and 2007, respectively. For the nine months ended September 30, 2008 and 2007, general and administrative expenses were $14.7 million and $8.6 million, respectively. General and administrative expenses increased as a result of additional employee costs due to the increase in headcount following the Avecia acquisition, as well as increased travel expenses, non-cash stock compensation expense, and increased legal and consulting expenses.

For the third quarter of 2008 PharmAthene's net loss attributable to common shareholders was $4.3 million or $0.20 per share, compared to $1.0 million or $0.07 per share in the same period of 2007. For the nine months ended September 30, 2008, the Company's net loss attributable to common shareholders was $31.2 million or $1.41 per share, compared to $12.6 million or $2.44 per share in the same period of 2007.

As of September 30, 2008, available cash, cash equivalents and short term investments were $13.2 million, excluding restricted cash totaling $14.5 million and gross proceeds from the Panacea Biotec investment of $13.1 million received in October 2008.

"The past several months have been an extraordinarily exciting time for PharmAthene as we continue to execute successfully against our objectives and achieve significant milestones in each of our biodefense programs," said David P. Wright, President and Chief Executive Officer.

"The next several months will be a pivotal time for our organization as we transition from a development company to one potentially generating product revenues if we are awarded a procurement contract for SparVax(TM)," continued Mr. Wright.

"We also strengthened our balance sheet in October 2008, adding gross proceeds of $13.1 million as part of a strategic investment by Panacea Biotec Ltd. Together these achievements provide a solid foundation from which to continue to advance our business objectives and build value for our shareholders," said Mr. Wright.

Conference Call and Webcast Information

PharmAthene management will host a conference call to discuss the Company's third quarter and nine month results on November 13, 2008, at 4:30 p.m., E.T. The dial-in number for U.S. callers is 800-798-2801 and for international callers is 617-614-6205. The participant passcode is 81927054.

A replay of the conference call will be available for 30 days, beginning at approximately 6:30 p.m. E.T. on November 13, 2008 until approximately 11:50 p.m. E.T. December 13, 2008. The dial-in number for U.S. callers is 888-286-8010, and for international callers is 617-801-6888. The participant passcode is 74215682.

The webcast of the conference call can be accessed from the company's website at A link to the webcast may be found on the Investor Relations section of the website.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
-- SparVax(TM) - a second generation recombinant protective antigen (rPA)

anthrax vaccine

-- Valortim(R) - a fully human monoclonal antibody for the prevention and

treatment of anthrax infection

-- Protexia(R) - a novel bioscavenger for the prevention and treatment of

morbidity and mortality associated with exposure to chemical nerve


-- RypVax(TM) - a recombinant dual antigen vaccine for plague

-- a third generation rPA anthrax vaccine.

For more information about PharmAthene, please visit

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the DHHS Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").

Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at



September 30, December 31,

2008 2007



Current assets:

Cash and cash equivalents $10,140,919 $40,582,643

Restricted cash 5,000,000 -

Short-term investments 3,107,108 12,153,945

Accounts receivable 10,912,569 4,005,693

Other receivables 543,309 1,240,069

Prepaid expenses and other current assets 844,375 492,294

Total current assets 30,548,280 58,474,645

Long-term restricted cash 9,500,000 -

Property and equipment, net 6,191,093 6,571,024

Patents, net 1,128,222 1,312,991

Other long-term assets 183,588 183,588

Deferred costs 251,193 68,884

Goodwill 2,502,909 -

Total assets $50,305,285 $66,611,132


Current Liabilities:

Accounts payable $3,205,696 $1,393,664

Accrued expenses and other liabilities 9,299,964 3,602,886

Note payable 12,932,973 -

Current portion of long-term debt 4,000,000 4,000,000

Total current liabilities 29,438,633 8,996,550

Other long-term liabilities 7,793,835 374,040

Long-term debt 1,904,936 16,668,458

Total liabilities 39,137,404 26,039,048

Stockholders' equity:

Common stock, $0.0001 par value; 100,000,000

shares authorized; 22,113,684 and

22,087,121 shares issued and outstanding;

respectively, at September 30, 2008 and

December 31, 2007 2,212 2,209

Additional paid-in capital 128,705,555 126,490,647

Accumulated other comprehensive income 1,075,828 1,481,779

Accumulated deficit (118,615,714) (87,402,551)

Total stockholders' equity 11,167,881 40,572,084

Total liabilities and stockholders' equity $50,305,285 $66,611,132



Three months ended Nine months ended

September 30, September 30,

2008 2007 2008 2007

(unaudited) (unaudited)

Contract revenue $10,643,705 $3,371,299 $27,377,207 $8,672,485

Other revenue 32,461 831 53,612 7,831

10,676,166 3,372,130 27,430,819 8,680,316

Operating expenses:

Research and

development 9,414,093 3,647,329 26,475,436 10,734,292

General and

administrative 4,803,190 3,150,894 14,655,971 8,605,147

Acquired in-process

research and

development 225,000 - 16,131,002 -

Depreciation and

amortization 205,409 209,420 641,425 518,713

Total operating

expenses 14,647,692 7,007,643 57,903,834 19,858,152

Loss from operations (3,971,526) (3,635,513) (30,473,015) (11,177,836)

Other income (expense):

Interest income 200,979 275,550 1,034,914 424,763

Gain on the

extinguishment of

debt - 1,206,743 - 1,206,743

Other income (expense) 49,035 - 49,035 -

Interest expense (628,470) (593,893) (1,947,245) (1,365,165)

Change in market

value of derivative

instruments 7,604 2,430,199 123,148 2,423,370

Total other expense (370,852) 3,318,599 (740,148) 2,689,711

Net loss (4,342,378) (316,914) (31,213,163) (8,488,125)

Accretion of



preferred stock to

redemptive value - (653,197) - (4,133,733)

Net loss

attributable to

common shareholders $(4,342,378) $(970,111) $(31,213,163) $(12,621,858)

Basic and diluted net

loss per share $(0.20) $(0.07) $(1.41) $(2.44)

Weighted average

shares used in

calculation of

basic and diluted

net loss per share 22,095,545 14,154,116 22,089,949 5,181,823

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
2. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
3. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
4. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
5. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
6. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
7. PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
8. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
9. PharmAthene Reports Second Quarter 2008 Financial and Operational Results
10. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
11. PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... ... with the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s ... hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading provider ... nationwide oncology Clinical Nurse Educator (CNE) network, which will launch ... for communication among health care professionals to enhance the patient ... office staff, and other health care professionals to help women ... cancer. ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
Breaking Biology Technology:
(Date:6/30/2017)... June 30, 2017 Today, American Trucking ... supplier of face and eye tracking software, became ... provider program. "Artificial intelligence and ... to monitor a driver,s attentiveness levels while on ... able to detect fatigue and prevent potential accidents, ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at  under "SEC ... . 2016 Year Highlights: Acquisition ...
Breaking Biology News(10 mins):